Granted Patent
B2
US 12,673,918 · App. 17/781,507 · Granted Jul 7, 2026
Small molecule RPN13 inhibitors with antitumor properties
Assignee:
THE JOHNS HOPKINS UNIVERSITY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds of formula (I), (II), and (III) having the structure shown below are presented: wherein R-R 6 are defined herein. These molecules work as proteasome inhibitors and bind to the RPN13 subunit of the 19S regulatory particle, and can be used in methods of treating a condition or a disease, such as cancer, in a mammal.
Claims (34)
1 . A compound of formula (I):
wherein
R is H, C(O)CH 2 Cl, C(O)CH 3 , C(O)CH═CH 2 , or C(O)N(H) CH 3 ;
R 1 at each occurrence is independently selected from NO 2 , halogen, and
R 2 is a side group from an alpha amino acid;
R 3 is C 1 -C 6 alkyl, or phenyl, wherein C 1 -C 6 alkyl is a saturated, linear or branched carbon chain having up to 6 carbons;
and n at each occurrence is independently an integer from 0-5, inclusive;
or a pharmaceutically acceptable salt, hydrate, or solvate thereof;
wherein when R 2 is the benzyl side group from phenylalanine and R 3 is hydrogen, R is C (O)CH 2 Cl; and
wherein the compound of formula (I) is not
2 . The compound of claim 1 wherein R 3 is methyl.
3 . The compound of claim 1 , wherein R 2 is the (CH 2 ) 4 NH 2 side group from lysine or the benzyl side group from phenylalanine.
4 . The compound of claim 1 , wherein R 2 is the benzyl side group from phenylalanine; and R is C(O)CH 2 Cl.
5 . The compound of claim 4 , wherein each (R 1 ) n is 3,4-dichloro, 4-nitro, 2-fluoro or 4-fluoro.
6 . The compound of claim 5 , selected from the group consisting of
7 . The compound of claim 1 , wherein R 2 is the benzyl side group from phenylalanine; R is H or C(O)CH 2 Cl;
R is nitro or fluorine; and
R 3 is methyl.
8 . The compound of claim 7 , selected from the group consisting of:
9 . The compound of claim 1 , wherein, when R3-methyl, the configuration at Carbon 2 of formula (I) is the R configuration, S configuration, or equimolar mixture of R and S.
10 . The compound of claim 9 , wherein the configuration at Carbon 2 is the S configuration.
11 . A method of treating a condition or a disease in a mammal by administering to the mammal a therapeutically effective dose of a compound of claim 1 to the mammal.
12 . The method of claim 11 , wherein the compound is selected from the group consisting of:
13 . The method of claim 11 , wherein the condition or disease is a type of cancer.
14 . The method of claim 13 , wherein the cancer is selected from the group consisting of breast cancer, cervical cancer, ovarian cancer, multiple myeloma, breast cancer, pancreatic cancer, and a cancer associated with Human Papilloma Virus (HPV).
15 . The method of claim 13 , wherein the cancer is ovarian cancer.
16 . The method of claim 11 , wherein the compound is administered in combination with at least one other therapeutic agent.
17 . The method of claim 16 , wherein the at least one other therapeutic agent is a proteasome inhibitor or a DNA damaging agent, bortezomib or cisplatin.
18 . The compound of claim 1 , wherein
R is H, or C(O)CH 2 Cl;
R 1 is NO 2 or halogen;
n is 1 or 2;
R 2 is benzyl; and
R 3 is methyl.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 3, 2022
From: RODEN, RICHARD B.S.; ANCHOORI, RAVI K.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 061292/0832 →
Continuity (3)
Provisional Application
63057778
· Jul 28, 2020
Provisional Application
62944957
· Dec 6, 2019
References Cited (81)
US 9913834B2
· Roden
· 2018
[cited by examiner]
US 20070270464A1
· Liotta et al.
· 2007
[cited by applicant]
WO 2019152536A1
· 2019
[cited by applicant]
Cresta et al., “Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours”, Eur J Cancer, (2008), vol. 44, pp. 1829-1834.
[cited by applicant]
Aghajanian et al., “A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study”, Gynecol Oncol., (2009), vol. 115, pp. 2…
[cited by applicant]
Parma et al., “An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens”, Int J Gynecol Cancer, (2012),…
[cited by applicant]
Kobrinsky et al., “A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity”, Cancer Chemother Pharmacol., (2013), vol. 72, pp. 1073-1078.
[cited by applicant]
Jandial et al., “A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study”, Gynecol Oncol., …
[cited by applicant]
Grice et al., “The recognition of ubiquitinated proteins by the proteasome”, Cell Mol Life Sci., (2016), vol. 73, pp. 3497-3506.
[cited by applicant]
Hamazaki et al., “Redundant Roles of Rpn10 and Rpn13 in Recognition of Ubiquitinated Proteins and Cellular Homeostasis”, PLoS Genet., (2015), vol. 11, No. 7, e1005401, (20 pages).
[cited by applicant]
Berko et al., “Inherent asymmetry in the 26S proteasome is defined by the ubiquitin receptor RPN13”, J Biol Chem., (2014), vol. 289, No. 9, pp. 5609-5618.
[cited by applicant]
Hemmis et al., “Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13”, J Biol Chem., (2019), vol. 294, No. 25, pp. 9659-9665.
[cited by applicant]
Aguileta et al., “The E3 ubiquitin ligase parkin is recruited to the 26 S proteasome via the proteasomal ubiquitin receptor Rpn13”, J Biol Chem, (2015), vol. 290, No. 12, pp. 7492-7505.
[cited by applicant]
Al-Shami et al., “Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development”, PLoS One, (2010), vol. 5, Issue 10, e13654, (11 pages).
[cited by applicant]
Jandial et al., “Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1”, Clin Cancer Res., (2009), vol. 15, No. 2, pp. 553-560.
[cited by applicant]
Jannuzzi et al., “Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib”, Redox Biol., (2020), vol. 32, 101502, (12 pages).
[cited by applicant]
Ling et al., “Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells”, J Biol Chem., (2003)…
[cited by applicant]
Ludman et al., “Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy”, Mol Pain, (2019), vol. 15, pp. 1-17.
[cited by applicant]
Mofers et al., “Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15”, PLoS One, (2019), vol. 14, No. 10, e0223807, (17 pages).
[cited by applicant]
Perez-Galan et al., “The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status”, Blood, (2006), vol. 107, No. 1, pp. 257-264.
[cited by applicant]
Roby et al., “Development of a syngeneic mouse model for events related to ovarian cancer”, Carcinogenesis, (2000), vol. 21, No. 4, pp. 585-591.
[cited by applicant]
Rowinsky et al., “Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma”, Invest New Drugs, (2020), vol. 38, pp. 1448-1453.
[cited by applicant]
Schwertman et al., “Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers”, Nat Rev Mol Cell Biol., (2016), vol. 17, pp. 379-394.
[cited by applicant]
Wang et al., “Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15”, Chem Biol Drug Des., (2015), vol. 86, pp. 1036-1048.
[cited by applicant]
Wilson et al., “Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease”, Nat Genet., (2002), vol. 32, pp. 420-425.
[cited by applicant]
Xing et al., “A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.”, Cancer Res., (2006), vol. 66, No. 18, pp. 8949-8953.
[cited by applicant]
Zheng et al., “Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy”, Exp Neurol., (2012), vol. 238, pp. 225-234.
[cited by applicant]
Conejo-Garcia et al., “Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A”, Nat Med., (2004), vol. 10, No. 9, pp. 950-958.
[cited by applicant]
Hochstrasser, “Ubiquitin and intracellular protein degradation”, Curr Opin Cell Biol., (1992), vol. 4, No. 6, pp. 1024-1031.
[cited by applicant]
Dou et al., “Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second-generation proteasome inhibitors versus future generation inhibitors of ubiquitin proteasome system”, Curr …
[cited by applicant]
Broyl et al., “Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial”, Lancet O…
[cited by applicant]
Vanderlinden et al., “Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism”, J Biol Chem., (2017), vol. 292, No. 23, pp. 9493…
[cited by applicant]
Liu et al., “Structural basis for the recognition of K48-linked Ub chain by proteasomal receptor Rpn13”, Cell Discov., (2019), 5:19 (15 pages).
[cited by applicant]
Lu et al., “Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets”, Nat Commun., (2017); 8:15540, (13 pages).
[cited by applicant]
Lu et al., “A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells”, PLoS One, (2015); 10(10):e0140518 (13 pages).
[cited by applicant]
Chen et al., “Structural plasticity allows UCH37 to be primed by RPN13 or locked down by INO80G”, Mol Cell., (2015), vol. 57, pp. 767-768.
[cited by applicant]
Jiao et al., “Mechanism of the Rpn13-induced activation of Uch37”, Protein Cell, (2014); vol. 5, No. 8, pp. 616-630.
[cited by applicant]
Anchoori et al., “A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer”, Cancer Cell, (2013), vol. 24, No. 6, pp. 791-805.
[cited by applicant]
Song et al., “Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma”, Leukemia, (2019), vol. 33, pp. 2685-2694.
[cited by applicant]
Song et al., “Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma”, Leukemia, (2016), vol. 30, pp. 1877-1886.
[cited by applicant]
Anchoori et al., “Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer”, ACS Omega, (2018), vol. 3, No. 9, pp. 11917-11929.
[cited by applicant]
Kisselev “A novel bullet hits the proteasome”, Cancer Cell., (2013), vol. 24, pp. 691-693.
[cited by applicant]
Randles et al., “The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression”, J Biol Chem., (2016), vol. 291, No. 16, pp. 8773-8783.
[cited by applicant]
Soong et al., “RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells”, Oncotarget, (2016); vol. 7, No. 42, pp. 68489-68502.
[cited by applicant]
Jiang et al., “Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma”, J Ovarian Res., (2017), vol. 10:53, (12 pages).
[cited by applicant]
Yu et al., “RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis”, Cell Physiol Biochem., (2018), vol. 47, pp. 1152-1166.
[cited by applicant]
Rao et al., “Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome”, Front. Chem., (2018), vol. 6, Article 392, (13 pages).
[cited by applicant]
Fejzo et al., “Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target”, Genes Chromosomes Cancer, (2008), vol. 47, pp. 873-883.
[cited by applicant]
Fejzo et al., “Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer”, Int J Mol Sci., (2013), vol. 14, pp. 3094-3109.
[cited by applicant]
Lee et al., “Proteasome Inhibitors disrupt the unfolded protein response in myeloma cells”, Proc Natl Acad Sci USA, (2003), vol. 100, No. 17, pp. 9946-9951.
[cited by applicant]
Smith et al., “Road to ruin: targeting proteins for degradation in the endoplasmic reticulum”, Science, (2011), vol. 334, pp. 1086-1090.
[cited by applicant]
Nawrocki et al., “Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis”, Cancer Res., (2005), vol. 65, No. 24, pp. 11658-11666.
[cited by applicant]
Walter et al., “The unfolded protein response: from stress pathway to homeostatic regulation”, Science, (2011), vol. 334, 1081-1086.
[cited by applicant]
Maharjan et al., “Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition”, Sci Rep., (2014), 4:5896, (11 pages).
[cited by applicant]
Starheim et al., “Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells”, Blood Cancer J., (2016), vol. 6:e446, (8 pages).
[cited by applicant]
Tsuboi et al., “Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance”, J Am Chem Soc., (2011), vol. 133, pp. 16605-16616.
[cited by applicant]
Ramkumar et al., “Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor”, Nat Commun., (2016); 7:13084, (13 pages).
[cited by applicant]
Ianevski et al., “SynergyFinder: a web application for analyzing drug combination dose-response matrix data”, Bioinformatics, (2017), vol. 33, No. 15, pp. 2413-2415.
[cited by applicant]
D'Arcy et al., “Inhibition of proteasome deubiquitinating activity as a new cancer therapy”, Nat Med., (2011), vol. 17, No. 12, pp. 1636-1640.
[cited by applicant]
Wang et al., “The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells”, Sci Rep., (2016), 6:26979, (15 pages).
[cited by applicant]
Ri et al., “Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress”, Leukemia, (2010), vol. 24, pp. 1506-1512.
[cited by applicant]
Robak et al., “Drug resistance in multiple myeloma”, Cancer Treat Rev., (2018), vol. 70, pp. 199-208.
[cited by applicant]
Walerych et al., “Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer”, Nat Cell Biol., (2016), vol. 18, No. 8, pp. 897-909.
[cited by applicant]
Ogiwara et al., “Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers”, Cancer Cell., (2019), vol. 35, pp. 177-190.
[cited by applicant]
Anglesio et al., “Type-specific cell line models for type-specific ovarian cancer research”, PLoS One, (2013), vol. 8, Issue 9, e72162, (13 pages).
[cited by applicant]
Strauss et al., “The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines”, Cancer Res., (2007), vol. 67, No. 6, pp. 2783-2…
[cited by applicant]
Qin et al., “Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells”, Cancer Res., (2005), vol. 65, No. 14, pp. 6282-6293.
[cited by applicant]
Liu et al., “Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy”, Cell Res., (2011), vol. 21, pp. 867-883.
[cited by applicant]
Luker et al., “Imaging 26S proteasome activity and inhibition in living mice”, Nat Med., (2003), vol. 9, No. 7, pp. 969-973.
[cited by applicant]
Lau et al., “Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin”, Cancer Res., (1991), vol. 51, pp. 5181-5187.
[cited by applicant]
Bazzaro et al., “alpha,beta-unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical…
[cited by applicant]
Anchoori et al., “Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells”, PLoS One, (2011), vol. 6, Issue 8, e23888, (10 pages).
[cited by applicant]
Coughlin et al., “Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses”, Clin Cancer Res., (2014), vol. 20, No. 12, pp. 3174-3186.
[cited by applicant]
DeBerardinis et al., “Fundamentals of cancer metabolism”, Sci Adv., (2016), vol. 2, :e1600200, (18 pages).
[cited by applicant]
Chen et al., “Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis”, Cell Rep., (2017), vol. 18, pp. 3143-3154.
[cited by applicant]
Bazzaro et al., “Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis”, Cancer Res., (2006), vol. 66, No. 7, pp. 3754-3763.
[cited by applicant]
Aghajanian et al., “Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer”, J Clin Oncol., (2005), vol. 23, No. 25, pp. 5943-5949.
[cited by applicant]
Ramirez et al., “Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer”, Gynecol Oncol., (2008), vol. 108, pp. 68-71.
[cited by applicant]
International Search Report and Writen Opinion issued in corresponding International Application No. PCT/US2020/063456 on Mar. 31, 2021.
[cited by applicant]